The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their sequelae by administration of 15-OHEPA.

A pharmaceutical composition or a cosmetic composition for treating hair loss, or promoting hair growth is described. The composition according to the present invention exhibits an excellent effect of treating hair loss and promoting hair growth, and can be safely used regardless of sex and age.

A pharmaceutical composition or a cosmetic composition for treating hair loss, or promoting hair growth is described. The composition according to the present invention exhibits an excellent effect of treating hair loss and promoting hair growth, and can be safely used regardless of sex and age.

A pharmaceutical composition or a cosmetic composition for treating hair loss, or promoting hair growth is described. The composition according to the present invention exhibits an excellent effect of treating hair loss and promoting hair growth, and can be safely used regardless of sex and age.

Compositions comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid, an ester derivative, or a pharmaceutically acceptable salt thereof; a triglyceride; and a surfactant, as well as methods for their use. The present disclosure further relates to self-emulsifying drug delivery systems, such as SEDDS, SMEDDS, or SNEDDS comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid.

Compositions comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid, an ester derivative, or a pharmaceutically acceptable salt thereof; a triglyceride; and a surfactant, as well as methods for their use. The present disclosure further relates to self-emulsifying drug delivery systems, such as SEDDS, SMEDDS, or SNEDDS comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid.

Use of ABTL0812 in the treatment of a cancer in a human patient, wherein the cancer treatment is related to chemotherapy, targeted therapy treatment, immunotherapy treatment or radiotherapy treatment.

Use of ABTL0812 in the treatment of a cancer in a human patient, wherein the cancer treatment is related to chemotherapy, targeted therapy treatment, immunotherapy treatment or radiotherapy treatment.

The present disclosure provides methods of treating diabetic retinopathy and ocular inflammatory diseases with anti-ceramide antibodies and antibody fragments. Also provided are methods for treating subjects who have previously received treatment for diabetic retinopathy. In some embodiments, the disclosure further provides methods of treating diabetic retinopathy with a single dose of an anti-ceramide antibody or antigen-binding fragment thereof.

Described herein is a method of treating pain by administering to a subject in need of treatment for pain a pharmaceutical composition including a therapeutically effective amount of margaric acid. Also described are pharmaceutical compositions such as topical and transdermal compositions including margaric acid and a pharmaceutically acceptable excipient. Further described is a composition for the treatment of pain including margaric acid, eicosapentaenoic acid, and a pharmaceutically acceptable excipient.